ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
DE-122 flops in wet AMD trial pharmatimes
March 12, 2020Tracon Pharmaceuticals and Santen have decided to halt development of DE-122 for wet age-related macular degeneration (AMD), after reviewing recently obtained top-line data from the Phase IIa AVANTE clinical study.
Pharma Sources Insight July 2025
